GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Change In Receivables

Pharmesis International (SGX:BFK) Change In Receivables : S$-0.42 Mil (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International Change In Receivables?

Pharmesis International's change in receivables for the quarter that ended in Jun. 2024 was S$0.02 Mil. It means Pharmesis International's Accounts Receivable declined by S$0.02 Mil from Dec. 2023 to Jun. 2024 .

Pharmesis International's change in receivables for the fiscal year that ended in Dec. 2023 was S$0.88 Mil. It means Pharmesis International's Accounts Receivable declined by S$0.88 Mil from Dec. 2022 to Dec. 2023 .

Pharmesis International's Accounts Receivable for the quarter that ended in Jun. 2024 was S$1.25 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Pharmesis International's Days Sales Outstanding for the six months ended in Jun. 2024 was 51.12.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pharmesis International's liquidation value for the six months ended in Jun. 2024 was S$-1.87 Mil.


Pharmesis International Change In Receivables Historical Data

The historical data trend for Pharmesis International's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International Change In Receivables Chart

Pharmesis International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 0.51 -0.35 0.19 0.88

Pharmesis International Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 -0.97 1.33 -0.44 0.02

Pharmesis International Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$-0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmesis International  (SGX:BFK) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Pharmesis International's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.246/4.448*91
=51.12

2. In Ben Graham's calculation of liquidation value, Pharmesis International's accounts receivable are only considered to be worth 75% of book value:

Pharmesis International's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.642-4.866+0.75 * 1.246+0.5 * 2.845
=-1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmesis International Change In Receivables Related Terms

Thank you for viewing the detailed overview of Pharmesis International's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmesis International Business Description

Traded in Other Exchanges
N/A
Address
5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International Headlines